Bioteque (ROCO:4107) Short-Term Debt: NT$131 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4107 Bioteque Corp ROCO:4107
86 GF Score
Price NT$114.00
GF Value NT$130.57
Valuation Modestly Undervalued
View Full Analysis

What is Bioteque Short-Term Debt?

Bioteque ROCO:4107 86 Short-Term Debt is NT$131 Mil as of Jun. 2026. GuruFocus rates ROCO:4107 with a GF Score™ of 86/100 and a GF Value™ of NT$130.57 (Modestly Undervalued).

Bioteque's Short-Term Debt for the quarter that ended in Jun. 2026 was NT$131 Mil.

Bioteque's quarterly Short-Term Debt declined from Dec. 2025 (NT$143 Mil) to Mar. 2026 (NT$130 Mil) but then increased from Mar. 2026 (NT$130 Mil) to Jun. 2026 (NT$131 Mil).

Bioteque's annual Short-Term Debt increased from Dec. 2023 (NT$148 Mil) to Dec. 2024 (NT$150 Mil) but then declined from Dec. 2024 (NT$150 Mil) to Dec. 2025 (NT$143 Mil).

Bioteque Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Bioteque Short-Term Debt Related Terms

Bioteque Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Bioteque's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioteque Short-Term Debt Chart

Bioteque Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.32 34.29 147.67 150.09 143.27

Bioteque Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 151.02 147.26 143.27 130.15 131.07
ROCO:4107
86GF Score
Bioteque Corp ROCO:4107
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$131 Mil mean?
Bioteque (ROCO:4107) has a Short-Term Debt of NT$131 Mil as of Jun. 2026.
Is Bioteque's Short-Term Debt too high?
Bioteque's current Short-Term Debt is NT$131 Mil. Overall, Bioteque has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioteque's Short-Term Debt compare to ISRG and BDX?
Bioteque's Short-Term Debt of NT$131 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Bioteque's current Short-Term Debt is NT$131 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioteque stock overvalued right now?
Based on GuruFocus' analysis, Bioteque (ROCO:4107) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$130.57, compared to a current price of NT$114.00 — trading 12.7% below its estimated fair value. The current Short-Term Debt is NT$131 Mil. Bioteque's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Bioteque (ROCO:4107), the current Short-Term Debt is NT$131 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioteque (ROCO:4107) Overvalued in 2026?

Based on GuruFocus' analysis, Bioteque stock appears to be undervalued. The current stock price of NT$114.00 is trading 12.7% below its estimated GF Value™ of NT$130.57. GuruFocus considers Bioteque to be Modestly Undervalued.

Key valuation signals for ROCO:4107:

  • Short-Term Debt: NT$131 Mil
  • GF Value™: NT$130.57 vs. price of NT$114.00 (12.7% below fair value)
  • GF Score™: 86/100

No single metric tells the full story. See the ROCO:4107 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioteque Business Description

Address Chang-An E. Road, 5th Floor-6, No.23, Section 1, Taipei, TWN, 104
Bioteque Corp is engaged in manufacturing, trading, and selling medical equipment and instruments. The company operates in different segments such as Manufacturing medical disposables for hemodialysis use, and selling them to dealers and retailers; Manufacturing and selling catheters for healthcare and medical PVC IV bags to medical organizations; Manufacturing and selling medical key components and inner catheters to the medical organization; and Other segment. Geographically, the company generates a majority of its revenue from Asia and the rest from North America, South America, and other regions.
86GF Score

Get the complete analysis for ROCO:4107

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$114.00
Price
NT$130.57
GF Value